Agricultural workers, veterinarians, and steel and metal industry workers are at higher risk of developing idiopathic pulmonary fibrosis (IPF), a…
Articles by José Lopes, PhD
Results of a Phase 2 trial of Promedior’s PRM-151, a treatment candidate for idiopathic pulmonary fibrosis (IPF), show a…
Treatment with Ofev (nintedanib) may reduce the risk of death in patients with idiopathic pulmonary fibrosis (IPF),…
Treatment candidate GLPG1690 prevented lung function decline in a Phase 2 clinical trial of idiopathic pulmonary fibrosis (IPF) patients,…
Treatment with Esbriet (pirfenidone, Genentech) or Ofev (nintedanib, Boehringer Ingelheim), or with steroids was found to be safe…
Treatment with plant-derived aloperine reduces the severity of lung injury in a mouse model of pulmonary fibrosis, a new Chinese…
The University of California is creating a research institute that springs out of the blocks quickly to provide a faster,…
A vast majority of pulmonary fibrosis (PF) and cystic fibrosis (CF) patients would like to have the ability to…
An Australian study showed that AD-114, an investigative therapy for idiopathic pulmonary fibrosis (IPF) developed by AdAlta, prevented the…
Real-world data shows that treatment with Ofev (nintedanib, marketed by Boehringer Ingelheim) helps stabilize idiopathic pulmonary fibrosis (IPF)…